DNAzymes as molecular agents that manipulate Egr-1 gene expression.
In recent years, the arsenal of small-molecule synthetic nucleic acids as gene-specific "knock-down" agents has increased in scope and variety. The investigator has the choice of antisense oligonucleotides, ribozymes, siRNA and DNAzymes, each subclass further benefiting from modifications that increase stability and efficiency and decrease toxicity. This review describes our use of DNAzymes in efforts to define the roles of key transcription factor targets, first in cultured vascular cells, then in animal models of neovascularization and arterial thickening.
Khachigian
Levon M
LM
Department of Haematology, Centre for Vascular Research, University of New South Wales, Prince of Wales Hospital, Sydney, Australia. l.khachigian@unsw.edu.au
D000818:Animals; D021881:DNA, Catalytic / Q000494:pharmacology*; D004277:DNA, Single-Stranded / Q000235:genetics / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D018919:Neovascularization, Physiologic / Q000187:drug effects; D016337:RNA, Catalytic / Q000494:pharmacology
C400152:DNA enzyme ED5; D021881:DNA, Catalytic; D004277:DNA, Single-Stranded; D016337:RNA, Catalytic